<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This paper describes the use of a low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) in the treatment of a thrombotic episode in a patient with <z:hpo ids='HP_0001976'>anti-thrombin III deficiency</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Subcutaneous Fraxiparine, a low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi>, was successfully used in the initial treatment of a second thrombotic episode in this patient with good results--no clot extension and an almost complete resolution of <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This case demonstrates the advantages of using LMWH over conventional unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> (UFH) which include ease of administration and the rapid achievement of optimal anticoagulation in conjunction with a diminished need for laboratory monitoring </plain></SENT>
</text></document>